MedTrace Logo

Can Sensorimotor Function Predict Graft Rupture After ACL Reconstruction

NCT04162613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2026-04-29

No results posted yet for this study

Summary

In this longitudinal prospective cohort study including young people with anterior cruciate ligament (ACL) reconstruction, the investigators will evaluate if poor sensorimotor function at baseline can predict 1) graft rupture 2) the risk of contra-lateral ACL injury and 3) failure to return to sport/previous activity level within 3 years following ACL reconstruction.

Conditions

  • Anterior Cruciate Ligament Injuries

Interventions

OTHER

Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation

The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test. At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level.

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Umeå University

    lead OTHER

Principal Investigators

  • Anna Cronström, PhD · Umeå University

  • Charlotte Häger, Professor · Umeå University

Eligibility

Min Age
15 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2026-02-15
Completion
2026-02-15

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162613 on ClinicalTrials.gov